GLP-1 for Inflammation: What Autoimmune Patients Need to Know

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) reduce C-reactive protein by 44 to 55% across a meta-analysis of 13 randomized controlled trials. That magnitude of CRP reduction rivals biologic drugs used for autoimmune disease. The mechanism is partly weight loss, partly direct suppression of NF-kB and the NLRP3 inflammasome in immune cells. For the roughly 24 million Americans with autoimmune conditions, many of whom also carry excess weight, GLP-1 drugs look like a two-for-one solution: weight loss plus inflammation control.

The picture is more complicated than that. A 2025 real-world study of 290,770 matched patients found that GLP-1 RA users had a higher incidence of autoimmune thyroiditis (HR 1.30), ankylosing spondylitis (HR 1.30), psoriasis (HR 1.17), ulcerative colitis (HR 1.11), and rheumatoid arthritis (HR 1.08). No autoimmune condition has Phase III trial data for GLP-1 drugs. The evidence is a patchwork of secondary endpoints, retrospective analyses, and conference abstracts.

Below: the evidence graded condition by condition, the contradictory safety signal addressed, GLP-1 RAs compared to another repurposed immunomodulatory drug (low dose naltrexone), and practical guidance for autoimmune patients already taking or considering these medications.

How GLP-1 Receptor Agonists Reduce Inflammation

GLP-1 (glucagon-like peptide 1) is an incretin hormone released by L-cells in the small intestine after eating. Its primary role is insulin secretion. Synthetic GLP-1 receptor agonists (semaglutide, marketed as Ozempic and Wegovy; liraglutide, marketed as Victoza and Saxenda; tirzepatide, marketed as Mounjaro and Zepbound) amplify and extend this signal. They were designed for type 2 diabetes and obesity. The anti-inflammatory effects were an unexpected finding.

Three mechanisms drive the inflammation reduction.

NF-kB pathway suppression. Nuclear factor kappa-B is the master transcription factor controlling inflammatory gene expression. GLP-1 receptor activation on macrophages and monocytes directly inhibits NF-kB signaling, reducing downstream production of TNF-alpha, IL-6, and IL-1beta. A 2025 JCI review documented that TNF-alpha levels dropped within hours of GLP-1 RA administration, faster than any weight loss could explain.

NLRP3 inflammasome inhibition. The NLRP3 inflammasome is a protein complex that drives IL-1beta and IL-18 release, both potent pro-inflammatory cytokines implicated in rheumatoid arthritis, inflammatory bowel disease, and Hashimoto's thyroiditis. GLP-1 RAs suppress NLRP3 assembly in macrophages through cAMP-dependent signaling. NLRP3 is a particularly attractive target because it sits at the intersection of metabolic stress and immune activation. Cholesterol crystals, uric acid, and free fatty acids all activate NLRP3, meaning the inflammasome acts as a sensor that converts metabolic dysfunction into inflammatory output. By suppressing NLRP3, GLP-1 RAs may interrupt this metabolic-to-immune amplification loop.

Weight-dependent effects. Obesity itself is an inflammatory state. Visceral adipose tissue is not passive storage. It functions as an endocrine organ, secreting TNF-alpha, IL-6, leptin, and resistin. These adipokines sustain a chronic low-grade inflammatory baseline that worsens every autoimmune condition. Leptin in particular drives Th1 and Th17 polarization while suppressing regulatory T cells, a pro-autoimmune shift in immune balance. A 15 to 20% reduction in body weight (typical with semaglutide over 68 weeks) substantially lowers this adipose-driven inflammatory load.

Separating the weight-dependent from weight-independent anti-inflammatory effects has been one of the central challenges in the research. The JCI 2025 review attempted this separation by examining early-phase inflammatory changes before significant weight loss occurred. TNF-alpha and IL-6 dropped within the first week of GLP-1 RA administration, when body composition had not yet changed. This suggests direct receptor-mediated anti-inflammatory effects. Over months, the weight-dependent and weight-independent contributions converge and become difficult to disentangle.

Tirzepatide (Mounjaro, Zepbound) adds a second incretin pathway: it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Whether dual agonism produces different or greater anti-inflammatory effects compared to GLP-1 alone is unknown. Tirzepatide trials show slightly greater weight loss (up to 22.5% in SURMOUNT-1) and comparable or greater CRP reduction, but no tirzepatide-specific autoimmune data exists.

DPP-4 inhibitors (sitagliptin, saxagliptin) are a related drug class that prevents degradation of endogenous GLP-1. Their anti-inflammatory effects are weaker than injectable GLP-1 RAs, likely because they raise GLP-1 levels modestly (2 to 3 fold) compared to the supraphysiological levels achieved by semaglutide (10 fold or more). DPP-4 inhibitors are not discussed further here because their anti-inflammatory signal is too small to be clinically relevant for autoimmune patients.

The 13-RCT meta-analysis showing 44 to 55% CRP reduction was published across studies in patients with type 2 diabetes and obesity. CRP is a nonspecific inflammatory marker; the reduction does not tell us which autoimmune pathways are being modified. Reducing CRP by half looks striking on a lab report but does not necessarily translate to reduced joint destruction, fewer psoriatic plaques, or lower autoantibody titers.

Evidence by Autoimmune Condition

No autoimmune condition reaches Grade A evidence for GLP-1 RAs. The strongest signal is in psoriasis among patients with concurrent metabolic disease. The weakest and most concerning is Hashimoto's thyroiditis, where the data points toward potential harm rather than benefit.

Psoriasis (Grade B in Obese/T2D Populations)

A 2025 randomized controlled trial enrolled patients with moderate-to-severe psoriasis and concurrent obesity or type 2 diabetes. Semaglutide reduced mean PASI scores from 21 to 10 over 12 weeks, a statistically significant improvement (p = 0.002). PASI 10 represents mild psoriasis. Moving a patient from PASI 21 (moderate-severe) to PASI 10 in three months is a meaningful clinical outcome.

The critical qualifier: liraglutide showed no psoriasis benefit in glucose-tolerant patients without metabolic disease. A separate RCT enrolled psoriasis patients with normal glucose tolerance and randomized them to liraglutide or placebo. No difference in PASI scores. This contrast suggests the psoriasis benefit is largely metabolic-mediated rather than a direct immunomodulatory effect. The GLP-1 RA treats the obesity that worsens psoriasis, not the psoriasis itself.

The metabolic mediation theory aligns with what dermatologists already know: psoriasis and metabolic syndrome share inflammatory pathways through IL-17, TNF-alpha, and adipokine signaling. Patients with psoriasis have a 40 to 60% higher prevalence of metabolic syndrome compared to the general population. Resolving the metabolic component removes one layer of inflammatory drive, even if the core autoimmune pathology persists.

For psoriasis patients with concurrent obesity or insulin resistance, GLP-1 RAs offer a dual benefit worth discussing with a dermatologist. For lean psoriasis patients, the evidence does not support off-label use for skin disease.

Rheumatoid Arthritis and Psoriatic Arthritis (Grade C)

Data presented at ACR Convergence 2025 described disease-modifying effects of GLP-1 RAs in RA, including reduced inflammatory cytokine levels and improved joint outcomes. These findings came from observational and retrospective studies, not prospective RCTs. No trial has compared GLP-1 RAs head-to-head against methotrexate, biologics, or JAK inhibitors in RA.

The mechanistic rationale is sound. NF-kB and NLRP3 are central to RA synovial inflammation, and GLP-1 RAs suppress both. The weight reduction component is also relevant: obesity is an independent predictor of poor response to TNF inhibitors in RA. Patients who lose weight on GLP-1 RAs may respond better to their existing RA medications.

Grade C reflects the absence of controlled trials. Conference abstracts and retrospective analyses generate hypotheses. They do not establish efficacy.

One practical consideration: obesity is common in RA and independently worsens disease outcomes. A 2021 analysis found that obese RA patients had 60% lower odds of achieving remission on TNF inhibitors compared to normal-weight patients. If GLP-1 RAs bring an obese RA patient closer to a healthy weight, the downstream improvement in biologic drug responsiveness could matter more than any direct anti-inflammatory effect of the GLP-1 RA itself. This indirect benefit is real but distinct from the claim that GLP-1 RAs treat RA.

For the strongest evidence-based approaches to RA inflammation, see our guide to best supplements for autoimmune disease, where omega-3 and curcumin hold Grade A evidence for RA specifically.

Inflammatory Bowel Disease (Grade C)

A 2025 meta-analysis published in the Journal of Crohn's and Colitis (ECCO-JCC) pooled retrospective data on GLP-1 RA users with concurrent IBD. Crohn's disease patients showed reduced surgical intervention rates. Ulcerative colitis patients had fewer adverse outcomes. The analysis could not determine whether these benefits stemmed from weight loss, direct anti-inflammatory action on gut tissue, or reduced metabolic comorbidities.

GLP-1 receptors are expressed on intestinal epithelial cells and enteric neurons, providing a plausible pathway for direct gut effects. Animal studies show that GLP-1 RA administration reduces intestinal inflammation in colitis models through NLRP3 suppression and enhanced mucosal barrier function. These preclinical findings have not translated into IBD-specific clinical trials.

GI side effects are a practical concern. Nausea, vomiting, and delayed gastric emptying are common with GLP-1 RAs, occurring in 20 to 50% of patients across trials. For IBD patients already dealing with abdominal pain, diarrhea, and nausea from active disease, layering GLP-1 RA side effects onto existing GI symptoms can worsen quality of life even if underlying inflammation is reduced. Delayed gastric emptying (gastroparesis) is particularly relevant for Crohn's patients, who may already have motility disorders from small bowel involvement.

There is also a diagnostic challenge. If a Crohn's patient on semaglutide develops new nausea and vomiting, is it a drug side effect or a disease flare? Distinguishing between the two requires imaging, endoscopy, or inflammatory marker testing, adding complexity to clinical management.

IBD-specific compound research such as BPC-157 for gut healing addresses gut inflammation through different pathways, though BPC-157 also lacks human RCT data.

Hashimoto's Thyroiditis (Inconclusive, Monitoring Required)

The 2025 real-world study raises the most concerning signal. Among 290,770 matched patients, GLP-1 RA users showed a hazard ratio of 1.30 for developing autoimmune thyroiditis compared to non-users. This means a 30% relative increase in the risk of new autoimmune thyroid disease.

Interpreting this finding requires caution. The study was observational. Patients prescribed GLP-1 RAs for type 2 diabetes or obesity may have a higher baseline risk for autoimmune thyroiditis due to shared metabolic and inflammatory risk factors. Confounding by indication (the reason for prescribing the drug correlates with the outcome being measured) is a known limitation of observational pharmacoepidemiology.

No study has measured the effect of GLP-1 RAs on TPO antibodies, thyroglobulin antibodies, or thyroid function in patients with established Hashimoto's. The increased incidence of new autoimmune thyroiditis does not tell us whether GLP-1 RAs worsen existing disease.

Hashimoto's thyroiditis already affects an estimated 14 million Americans, making it the most common autoimmune disease in the United States. The overlap between Hashimoto's and obesity is substantial: hypothyroidism causes weight gain, fatigue, and metabolic slowing, which leads to GLP-1 RA prescriptions for weight management, which then raises the question of autoimmune thyroid effects. This circular relationship makes the observational data difficult to untangle.

For Hashimoto's patients currently taking or starting a GLP-1 RA for weight management or diabetes, monitoring is the reasonable approach. Check TSH, free T4, and thyroid antibodies at baseline and every 3 to 6 months. Report new symptoms (fatigue, weight gain, cold intolerance, neck pressure) to your endocrinologist. For a comprehensive approach to Hashimoto's natural treatment, including the evidence for selenium, myo-inositol, and dietary intervention, see our pillar guide.

The Contradictory Data: Can GLP-1 Drugs Trigger Autoimmunity?

The 2025 real-world study deserves detailed examination because it contradicts the prevailing narrative that GLP-1 RAs are purely anti-inflammatory.

The study used a matched cohort design. Researchers identified patients who initiated GLP-1 RAs and matched them 1:1 with non-users based on age, sex, BMI, and comorbidities. The analysis tracked new-onset autoimmune diagnoses over a median follow-up of 3.2 years. Hazard ratios for new autoimmune disease in GLP-1 RA users:

• Autoimmune thyroiditis: HR 1.30 (95% CI 1.18 to 1.44)
• Ankylosing spondylitis: HR 1.30 (95% CI 1.02 to 1.65)
• Psoriasis: HR 1.17 (95% CI 1.07 to 1.28)
• Ulcerative colitis: HR 1.11 (95% CI 0.98 to 1.26)
• Rheumatoid arthritis: HR 1.08 (95% CI 1.00 to 1.17)

Several points of context.

The confidence intervals for UC and RA cross 1.0, meaning these findings may not be statistically significant. Thyroiditis, AS, and psoriasis had more robust signals.

Observational data cannot establish causation. Patients prescribed GLP-1 RAs are metabolically different from the general population. Obesity drives systemic inflammation that may independently trigger autoimmune disease, and GLP-1 RA users, by definition, had indications for these drugs. The matching attempted to control for this, but residual confounding is impossible to eliminate without randomization.

Mendelian randomization studies (which use genetic variants as proxy exposures to approximate randomization) have provided partial but not definitive evidence for a causal relationship between GLP-1 receptor activation and autoimmune risk. These analyses are useful for generating hypotheses but have their own limitations in instrument strength and pleiotropy.

A biological mechanism for GLP-1 RA-triggered autoimmunity is not well established. Several hypotheses exist.

The first involves rapid weight loss. Visceral adipose tissue stores lipophilic toxins, persistent organic pollutants, and inflammatory mediators. During fat mobilization, these compounds are released into circulation. Rapid fat loss (15 to 20% of body weight over 12 to 18 months) could transiently spike the toxic and inflammatory load in a way that uncovers latent autoimmune susceptibility. This mechanism would implicate any effective weight loss intervention, not GLP-1 RAs specifically. Bariatric surgery data provides partial support: some studies show increased autoimmune diagnoses in the years following surgical weight loss.

The second involves GLP-1 receptor expression on immune cells. If GLP-1 RAs modulate immune cell function directly (suppressing some pathways while potentially activating others), the net effect could be anti-inflammatory in most contexts but pro-autoimmune in genetically susceptible individuals. Immune modulation is not immune suppression. Shifting immune balance in one direction may unmask autoimmune potential that was previously held in check by a different balance.

The third is detection bias. Patients on GLP-1 RAs see their physicians more frequently than the general population, have more blood work drawn, and undergo more comprehensive monitoring. Autoimmune conditions that would have gone undiagnosed in the general population may be detected earlier and more frequently in this more closely monitored group.

The practical takeaway: GLP-1 RAs are not recommended off-label for autoimmune disease. For patients taking GLP-1 RAs for their approved indications (T2D, obesity), the anti-inflammatory effects are a potential secondary benefit, not a primary goal. The autoimmune safety signal warrants monitoring, not discontinuation. Stopping an effective diabetes or obesity medication based on observational autoimmune risk data would be premature.

GLP-1 RAs vs LDN: Two Repurposed Drugs, Different Strategies

Both GLP-1 receptor agonists and low dose naltrexone are medications developed for one purpose and repurposed for anti-inflammatory effects. The comparison is instructive because they represent opposite ends of the accessibility spectrum.

GLP-1 RAs suppress NF-kB and NLRP3, reducing inflammatory cytokine production from macrophages and monocytes. LDN modulates TLR4 (Toll-like receptor 4) on microglia and macrophages, reducing neuroinflammation and peripheral inflammation through a different pathway. LDN also transiently blocks opioid receptors, triggering a compensatory upregulation of endogenous endorphins that modulate immune function.

The evidence gap is different in character. GLP-1 RAs have massive RCT data for metabolic endpoints, with anti-inflammatory effects documented as secondary findings across tens of thousands of patients. LDN has small Phase II trials directly targeting autoimmune conditions (Crohn's disease, multiple sclerosis, fibromyalgia), with Younger et al. demonstrating reduced inflammatory markers in fibromyalgia patients. Smith et al. (2007, 2011) showed endoscopic remission in 33% of Crohn's patients on LDN versus 8% on placebo, with 88% showing histological improvement. GLP-1 RA autoimmune evidence is indirect but large. LDN autoimmune evidence is direct but small.

The mechanistic profiles are complementary rather than overlapping. GLP-1 RAs primarily target macrophage and monocyte activation through NF-kB and NLRP3. LDN primarily modulates glial cell activation and T cell regulation through TLR4 and opioid receptor pathways. A patient could theoretically benefit from both, though no study has examined combined use and no physician should prescribe this combination without a specific clinical rationale.

Cost separates them dramatically. Branded semaglutide costs $800 to $1,300 per month. Compounded semaglutide is less expensive but faces evolving regulatory restrictions. LDN costs $30 to $50 per month through compounding pharmacies. Neither is FDA-approved for autoimmune disease, meaning insurance coverage for autoimmune use is unlikely for either.

For autoimmune patients weighing these options: LDN has a longer track record of off-label autoimmune use, more direct (if smaller) autoimmune trial data, and costs a fraction of GLP-1 RAs. GLP-1 RAs make sense when a patient has both autoimmune disease and a primary indication (obesity or T2D), where the anti-inflammatory effects become an added benefit of an already justified prescription. Using a GLP-1 RA solely for autoimmune inflammation, without a metabolic indication, lacks the evidence to support the cost and injection burden.

What This Means for Autoimmune Patients on GLP-1 Medications

Millions of autoimmune patients are already taking semaglutide or tirzepatide for weight loss or diabetes. The overlap between autoimmune disease and metabolic dysfunction is substantial: Hashimoto's thyroiditis causes weight gain through hypothyroidism, corticosteroid use in lupus and RA drives obesity, and chronic inflammation itself promotes insulin resistance. GLP-1 RAs address real clinical needs in this population.

Practical recommendations for autoimmune patients on GLP-1 RAs:

Monitor inflammatory markers. Track high-sensitivity CRP (hs-CRP) and ESR at baseline and every 3 to 6 months after starting a GLP-1 RA. If your rheumatologist or endocrinologist does not routinely order these, request them. Documenting the anti-inflammatory response (or lack thereof) provides useful data for ongoing treatment decisions. A meaningful CRP reduction on a GLP-1 RA tells you that systemic inflammation is declining. It does not tell you whether your specific autoimmune pathway is being modified. Disease-specific markers (TPO antibodies for Hashimoto's, anti-CCP for RA, PASI for psoriasis) provide better information about autoimmune disease activity.

Do not adjust autoimmune medications based on GLP-1 effects. A dropping CRP on semaglutide does not mean your methotrexate, hydroxychloroquine, or biologic can be reduced. Autoimmune disease activity and nonspecific inflammation are different things. Only your prescribing specialist should modify autoimmune medications, based on disease-specific markers and clinical assessment.

Watch for new autoimmune disease symptoms. The 2025 safety signal, while observational, justifies increased vigilance. New joint pain, rashes, thyroid symptoms, GI changes, or unusual fatigue after starting a GLP-1 RA should be reported to your physician and investigated, not attributed to medication side effects without workup.

Consider the weight loss benefit separately. For autoimmune patients with obesity, the weight loss from GLP-1 RAs may improve disease activity through reduced adipose-driven inflammation. This is a legitimate clinical benefit. Multiple autoimmune conditions (psoriasis, RA, IBD) show worse outcomes in obese patients and better treatment responses in patients who reach a healthy weight. The question is whether the anti-inflammatory effect of GLP-1 RAs extends beyond what weight loss alone would produce. For most autoimmune conditions, we do not know yet. The answer matters less than the outcome: if disease activity improves while on a GLP-1 RA, the cause (direct immunomodulation versus weight-mediated improvement) is less important than the result.

Maintain evidence-based supplementation. GLP-1 RAs do not replace foundational autoimmune support. Vitamin D3 (VITAL trial: 22% reduction in autoimmune incidence), omega-3 fatty acids, and condition-specific supplements retain their evidence base regardless of GLP-1 RA use. GLP-1 RAs can also affect nutrient absorption. Delayed gastric emptying changes the timing of nutrient uptake. Reduced food intake (a primary mechanism of the weight loss) may lead to inadequate intake of magnesium, B12, iron, and other micronutrients that autoimmune patients are already prone to losing. Monitor nutrient levels and adjust supplementation accordingly. For a complete overview, see our best supplements for autoimmune disease guide.

Communicate with all prescribers. Autoimmune patients often see multiple specialists: a rheumatologist, an endocrinologist, a dermatologist, and a primary care physician. If one prescribes a GLP-1 RA and another manages your autoimmune medications, ensure each knows what the other has prescribed. Drug interactions between GLP-1 RAs and common autoimmune medications (methotrexate, biologics, hydroxychloroquine) are not well studied. The delayed gastric emptying caused by GLP-1 RAs can alter the absorption kinetics of oral medications, potentially affecting drug levels.

Frequently Asked Questions

Does semaglutide reduce inflammation?

Yes. A meta-analysis of 13 RCTs found that semaglutide and other GLP-1 receptor agonists reduce C-reactive protein by 44 to 55%. The mechanism involves direct NF-kB suppression in immune cells and indirect effects through weight loss, which reduces adipose-derived inflammatory cytokines. A 2025 JCI review documented that TNF-alpha levels decrease within hours of administration, faster than weight loss can account for. The reduction is well-documented in metabolic disease populations. Whether it translates to improved outcomes in autoimmune disease specifically is unproven.

Can GLP-1 drugs help rheumatoid arthritis?

Data presented at ACR Convergence 2025 showed disease-modifying effects and cytokine reduction in RA patients using GLP-1 RAs, but this evidence came from observational studies, not randomized controlled trials. No trial has compared GLP-1 drugs against standard RA treatments (methotrexate, biologics, JAK inhibitors). GLP-1 RAs are not recommended off-label for RA. For RA patients who also have obesity or type 2 diabetes, the anti-inflammatory effects may provide secondary benefit when the drug is prescribed for its approved indication.

Are GLP-1 drugs safe for Hashimoto's patients?

A 2025 matched cohort study of 290,770 patients found a 30% higher rate of new autoimmune thyroiditis among GLP-1 RA users (HR 1.30). This observational finding does not prove causation, and no study has measured the effect on TPO antibodies or thyroid function in patients with established Hashimoto's. Hashimoto's patients taking GLP-1 RAs for obesity or diabetes should monitor TSH, free T4, and thyroid antibodies every 3 to 6 months. Discuss with your endocrinologist. Do not avoid a medically necessary GLP-1 RA based on this preliminary safety signal alone.

How do GLP-1 drugs compare to LDN for autoimmune inflammation?

GLP-1 RAs suppress NF-kB and NLRP3 inflammasome activation. LDN modulates TLR4 and upregulates endogenous endorphins. GLP-1 RAs cost $800 to $1,300 per month for branded versions; LDN costs $30 to $50 through compounding pharmacies. Neither is FDA-approved for autoimmune disease. LDN has more direct autoimmune trial data (Phase II in Crohn's, pilot studies in MS and fibromyalgia). GLP-1 RAs have stronger general anti-inflammatory data but from metabolic disease populations. For a detailed review of LDN for autoimmune disease, see our dedicated guide.

Should autoimmune patients take Ozempic for inflammation?

No. GLP-1 RAs including Ozempic (semaglutide) are not approved or recommended for autoimmune inflammation. They are prescribed for type 2 diabetes and obesity. Autoimmune patients who happen to need a GLP-1 RA for an approved indication may experience anti-inflammatory benefits as a secondary effect. Using Ozempic off-label solely for autoimmune inflammation lacks the clinical trial evidence to justify the cost, the injection burden, and the potential risks including the 2025 safety signal for increased autoimmune thyroiditis incidence.

Where the Evidence Stands

GLP-1 receptor agonists are genuine anti-inflammatory agents. The CRP data is robust. The NF-kB and NLRP3 mechanisms are well characterized. For autoimmune patients who also need treatment for obesity or type 2 diabetes, these medications offer a plausible dual benefit.

The gap between anti-inflammatory biomarker changes and autoimmune disease modification remains wide. No autoimmune condition has a Phase III GLP-1 RA trial. The strongest condition-specific evidence (psoriasis, Grade B) may reflect metabolic improvement rather than direct immunomodulation. The contradictory safety data raises questions that only prospective trials can resolve.

For patients seeking evidence-based approaches to autoimmune inflammation today, the established interventions hold stronger ground: vitamin D3, omega-3 fatty acids, condition-specific protocols, and dietary strategies like the AIP diet have direct autoimmune trial data and decades of safety follow-up.

Take the free 3-minute AutoimmuneFinder quiz to build a personalized, evidence-graded protocol matched to your specific condition, severity, and current medications.

This article is for educational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications with serious potential side effects. Do not start, stop, or change any medication without consulting your physician. All treatment decisions should be made in partnership with your healthcare provider.